Buoyed By Phase III Rosacea Success, Foamix Plans Commercial Transition
Market of dermatologists prescribing for rosacea and acne is very focused, so Foamix says it can manage commercialization of topical minocycline foam on its own.
You may also be interested in...
A roundup of new applications submitted to FDA’s Center for Drug Evaluation and Research.
A topical foam formulation of the antibiotic, minocycline, is expected to be a novel entrant into the US severe acne market. After positive top-line results from a confirmatory Phase III study, Foamix is stepping-up its financing and marketing plans.
LEO Pharma is buying branded topical treatments worth more than €280m in annual sales from Bayer. Also, Apricus and Sellos agree to merge, Lilly partners on translation inhibitors with Anima, and Merck leverages Sutro's technology in cancer and autoimmune partnership.